Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...

The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

Boehringer healthcare HCP Illustrative image Boehringer Ingelheim today announced top-line results from the Phase III CONNEX ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

The analyst from Canaccord Genuity noted Guardant Health (NASDAQ:GH)'s extensive experience in blood-based cancer detection ...

Revocation petition can be sustained even after expiry of patent: Delhi High Court: Gireesh Babu, New Delhi Wednesday, January 22, 2025, 08:00 Hrs [IST] The High Court of Delhi ha ...

TD Cowen reaffirmed its Buy rating on Guardant Health shares with a consistent price target of $42.00. The stock, currently ...